Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
Ionis Pharmaceuticals (IONS) reported a Q4 loss of $0.66 per share, which was better than the Zacks Consensus Estimate of a $1.12 loss. This is a larger loss compared to $0.06 per share a year ago.
February 19, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ionis Pharmaceuticals reported a Q4 loss of $0.66 per share, better than the expected $1.12 loss, but worse than last year's $0.06 loss.
The better-than-expected earnings per share loss suggests positive investor sentiment in the short term, despite the larger loss compared to last year.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100